The Non-alcoholic Steatohepatitis Biomarkers Market is expected to register a CAGR of 25% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Non-alcoholic Steatohepatitis Biomarkers Market report covers segmental analysis by Type (Serum biomarkers, Hepatic fibrosis biomarkers, Apoptosis biomarkers, Oxidative stress biomarkers, Others); Application (Pharmaceutical and CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries
Purpose of the ReportThe report Non-alcoholic Steatohepatitis Biomarkers Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Non-alcoholic Steatohepatitis Biomarkers Market Segmentation
Type- Serum biomarkers
- Hepatic fibrosis biomarkers
- Apoptosis biomarkers
- Oxidative stress biomarkers
- Pharmaceutical and CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
Strategic Insights
Non-alcoholic Steatohepatitis Biomarkers Market Growth Drivers- Rising Prevalence of NASH and Metabolic Diseases: The increasing global incidence of Non-alcoholic Steatohepatitis (NASH) and other metabolic disorders such as obesity and type 2 diabetes is a primary growth driver for the NASH biomarkers market. As these conditions often lead to liver inflammation and fibrosis, the demand for accurate and early detection tools using biomarkers is escalating. The NASH biomarkers market benefits from the growing need for diagnostics and prognostic tools to manage the progression of these chronic conditions effectively.
- Increasing Awareness and Early Diagnosis Initiatives: The rising awareness surrounding Non-alcoholic Steatohepatitis (NASH) and its potential progression to liver cirrhosis and cancer is pushing the demand for early diagnostic tools. Public health campaigns and educational programs aimed at increasing awareness about the significance of NASH are driving the demand for biomarkers. This heightened awareness is creating a more proactive approach to healthcare, encouraging earlier diagnosis and the use of NASH biomarkers to monitor liver health.
- Rising Investment in NASH Research and Drug Development: Significant investments in research and development aimed at discovering new drugs and treatments for NASH are directly fueling the NASH biomarkers market. As pharmaceutical companies invest in developing therapies for NASH, the need for reliable biomarkers to identify suitable candidates for clinical trials, monitor drug efficacy, and predict disease progression is increasing. This trend is accelerating market growth as the pharmaceutical sector seeks to integrate biomarkers into drug development pipelines.
- Collaboration Between Industry and Regulatory Bodies for Biomarker Validation: As the demand for NASH biomarkers increases, there will be a stronger push for collaborations between pharmaceutical companies, biotechnology firms, and regulatory bodies such as the U.S. FDA and EMA. These collaborations will help expedite the validation and approval process of new biomarkers for clinical use. Regulatory agencies are likely to support the development of biomarkers that improve clinical trial outcomes and treatment monitoring, paving the way for more accurate and reliable biomarkers to enter the market.
- Use of NASH Biomarkers in Monitoring Treatment Response: As more effective therapies for Non-alcoholic Steatohepatitis (NASH) are developed, biomarkers will play a critical role in monitoring patients’ responses to treatment. The future of the NASH biomarkers market will include a greater emphasis on identifying biomarkers that can track the effectiveness of pharmacological therapies, lifestyle interventions, and even surgical treatments. Biomarkers will enable clinicians to assess how well a treatment is working, allowing for timely adjustments and personalized treatment regimens.
- Patient-Centric and At-Home Testing Solutions: With the rise of patient-centric healthcare and the increasing demand for at-home testing, there will be a significant push for NASH biomarkers that can be used in home-based diagnostic kits. These solutions will empower patients to monitor their liver health regularly, especially in individuals with risk factors for NASH. As the market for at-home diagnostics grows, companies will develop user-friendly, affordable, and reliable biomarkers that can be used outside traditional healthcare settings, further expanding the reach of NASH biomarkers.
- Development of Multiplex Biomarker Panels for Comprehensive Diagnostics: The growing focus on early-stage NASH diagnosis presents an opportunity to develop multiplex biomarker panels that can simultaneously detect a range of biomarkers indicative of liver damage, inflammation, and fibrosis. These panels will offer more comprehensive and accurate diagnostics, improving the ability to monitor disease progression and evaluate treatment response. By providing multi-faceted insights, multiplex biomarkers will enhance clinicians’ ability to offer personalized treatment plans and will be in high demand as diagnostic tools in the market.
- At-Home and Point-of-Care Testing: With the increasing trend toward home healthcare and remote patient monitoring, there is a growing opportunity for the development of NASH biomarkers that can be used for at-home or point-of-care testing. Patients will benefit from the convenience of being able to monitor their liver health regularly, without the need for frequent hospital visits. At-home diagnostic solutions for NASH, such as simple blood tests or wearable devices that monitor liver biomarkers, represent a significant opportunity for the market to expand into consumer healthcare applications, improving accessibility and early detection of the disease.
- Regulatory Support and Market Incentives for Biomarker-Based Diagnostics: Government incentives and regulatory support for the development and commercialization of innovative biomarker-based diagnostics represent a crucial opportunity in the NASH biomarkers market. Regulatory bodies, such as the U.S. FDA, are increasingly fast-tracking approvals for biomarkers that show promise in diagnosing NASH or monitoring disease progression. As more biomarkers are validated and approved for clinical use, companies that focus on regulatory compliance and achieve faster approval timelines can gain a competitive advantage and expand their market share.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Non-alcoholic Steatohepatitis Biomarkers Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Non-alcoholic Steatohepatitis Biomarkers Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Non-alcoholic Steatohepatitis Biomarkers Market is expected to register a CAGR of 25% from 2025-2031.
The major factors impacting the Non-alcoholic Steatohepatitis Biomarkers Market are: Rising Prevalence of NASH and Metabolic Diseases, Increasing Awareness and Early Diagnosis Initiatives and Rising Investment in NASH Research and Drug Development
Key future trends in this market are - Collaboration Between Industry and Regulatory Bodies for Biomarker Validation, Use of NASH Biomarkers in Monitoring Treatment Response and Patient-Centric and At-Home Testing Solutions
Key companies of this market are: BioPredictive, Cisbio, Allergan, NGM Biopharmaceuticals, AstraZeneca, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Siemens Healthineers, Genfit
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Non-alcoholic Steatohepatitis Biomarkers Market - By Type
1.3.2 Non-alcoholic Steatohepatitis Biomarkers Market - By Application
1.3.3 Non-alcoholic Steatohepatitis Biomarkers Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET - GLOBAL MARKET ANALYSIS
6.1. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS - GLOBAL MARKET OVERVIEW
6.2. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. SERUM BIOMARKERS
7.3.1. Overview
7.3.2. Serum biomarkers Market Forecast and Analysis
7.4. HEPATIC FIBROSIS BIOMARKERS
7.4.1. Overview
7.4.2. Hepatic fibrosis biomarkers Market Forecast and Analysis
7.5. APOPTOSIS BIOMARKERS
7.5.1. Overview
7.5.2. Apoptosis biomarkers Market Forecast and Analysis
7.6. OXIDATIVE STRESS BIOMARKERS
7.6.1. Overview
7.6.2. Oxidative stress biomarkers Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. PHARMACEUTICAL AND CRO INDUSTRY
8.3.1. Overview
8.3.2. Pharmaceutical and CRO Industry Market Forecast and Analysis
8.4. HOSPITALS
8.4.1. Overview
8.4.2. Hospitals Market Forecast and Analysis
8.5. DIAGNOSTIC LABS
8.5.1. Overview
8.5.2. Diagnostic Labs Market Forecast and Analysis
8.6. ACADEMIC RESEARCH INSTITUTES
8.6.1. Overview
8.6.2. Academic Research Institutes Market Forecast and Analysis
9. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Non-alcoholic Steatohepatitis Biomarkers Market Overview
9.1.2 North America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis
9.1.3 North America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Type
9.1.4 North America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Application
9.1.5 North America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Non-alcoholic Steatohepatitis Biomarkers Market
9.1.5.1.1 Canada Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.1.5.1.2 Canada Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.1.5.2 Mexico Non-alcoholic Steatohepatitis Biomarkers Market
9.1.5.2.1 Mexico Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.1.5.2.2 Mexico Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.1.5.3 US Non-alcoholic Steatohepatitis Biomarkers Market
9.1.5.3.1 US Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.1.5.3.2 US Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.2. EUROPE
9.2.1 Europe Non-alcoholic Steatohepatitis Biomarkers Market Overview
9.2.2 Europe Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis
9.2.3 Europe Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Type
9.2.4 Europe Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Application
9.2.5 Europe Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Non-alcoholic Steatohepatitis Biomarkers Market
9.2.5.1.1 Germany Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.2.5.1.2 Germany Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.2.5.2 France Non-alcoholic Steatohepatitis Biomarkers Market
9.2.5.2.1 France Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.2.5.2.2 France Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.2.5.3 Italy Non-alcoholic Steatohepatitis Biomarkers Market
9.2.5.3.1 Italy Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.2.5.3.2 Italy Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.2.5.4 Spain Non-alcoholic Steatohepatitis Biomarkers Market
9.2.5.4.1 Spain Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.2.5.4.2 Spain Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.2.5.5 United Kingdom Non-alcoholic Steatohepatitis Biomarkers Market
9.2.5.5.1 United Kingdom Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.2.5.5.2 United Kingdom Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.2.5.6 Rest of Europe Non-alcoholic Steatohepatitis Biomarkers Market
9.2.5.6.1 Rest of Europe Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.2.5.6.2 Rest of Europe Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market Overview
9.3.2 Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis
9.3.3 Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Non-alcoholic Steatohepatitis Biomarkers Market
9.3.5.1.1 Australia Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.3.5.1.2 Australia Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.3.5.2 China Non-alcoholic Steatohepatitis Biomarkers Market
9.3.5.2.1 China Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.3.5.2.2 China Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.3.5.3 India Non-alcoholic Steatohepatitis Biomarkers Market
9.3.5.3.1 India Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.3.5.3.2 India Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.3.5.4 Japan Non-alcoholic Steatohepatitis Biomarkers Market
9.3.5.4.1 Japan Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.3.5.4.2 Japan Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.3.5.5 South Korea Non-alcoholic Steatohepatitis Biomarkers Market
9.3.5.5.1 South Korea Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.3.5.5.2 South Korea Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.3.5.6 Rest of Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market
9.3.5.6.1 Rest of Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.3.5.6.2 Rest of Asia-Pacific Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market Overview
9.4.2 Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis
9.4.3 Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Non-alcoholic Steatohepatitis Biomarkers Market
9.4.5.1.1 South Africa Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.4.5.1.2 South Africa Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.4.5.2 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market
9.4.5.2.1 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.4.5.2.2 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.4.5.3 U.A.E Non-alcoholic Steatohepatitis Biomarkers Market
9.4.5.3.1 U.A.E Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.4.5.3.2 U.A.E Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.4.5.4 Rest of Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market
9.4.5.4.1 Rest of Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.4.5.4.2 Rest of Middle East and Africa Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Non-alcoholic Steatohepatitis Biomarkers Market Overview
9.5.2 South and Central America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis
9.5.3 South and Central America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Type
9.5.4 South and Central America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Application
9.5.5 South and Central America Non-alcoholic Steatohepatitis Biomarkers Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Non-alcoholic Steatohepatitis Biomarkers Market
9.5.5.1.1 Brazil Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.5.5.1.2 Brazil Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.5.5.2 Argentina Non-alcoholic Steatohepatitis Biomarkers Market
9.5.5.2.1 Argentina Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.5.5.2.2 Argentina Non-alcoholic Steatohepatitis Biomarkers Market by Application
9.5.5.3 Rest of South and Central America Non-alcoholic Steatohepatitis Biomarkers Market
9.5.5.3.1 Rest of South and Central America Non-alcoholic Steatohepatitis Biomarkers Market by Type
9.5.5.3.2 Rest of South and Central America Non-alcoholic Steatohepatitis Biomarkers Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET, KEY COMPANY PROFILES
11.1. BIOPREDICTIVE
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. CISBIO
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ALLERGAN
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. NGM BIOPHARMACEUTICALS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ASTRAZENECA
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. NOVARTIS AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NOVO NORDISK A/S
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SIEMENS HEALTHINEERS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. GENFIT
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. BioPredictive
2. Cisbio
3. Allergan
4. NGM Biopharmaceuticals
5. AstraZeneca
6. Novartis AG
7. Novo Nordisk A/S
8. Pfizer, Inc.
9. Siemens Healthineers
10. Genfit
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For